“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.
Contenu original affiche; la traduction localisee n'est pas encore disponible.
Ce qui s'est passé
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.
Pourquoi c'est important
The development may change operating conditions or market expectations around AI. Further confirmation and measurable outcomes matter.
Entités concernées
Voir les preuves
1 articles · 1 publication d'origine · 1 independantes
- TechCrunch AISource primaire · Confirme · EN · 100%“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z ↗
Affirmations
- “We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z Observé
Divergences
Aucune divergence importante détectée dans les preuves disponibles.
Chronologie
- Premier signalement
Mouvement de marché suivant l'événement
La réaction du marché n'est pas encore disponible pour cet actif et cette fenêtre.